Agile gains as H.C. Wainwright sees 630% upside potential

Pgiam/iStock via Getty Images

• Agile Therapeutics (NASDAQ:AGRX) rose sharply in the early trading on Monday after H.C. Wainwright doubled the price target on the women's healthcare company to a Street high of $5.00, citing its prospects following the recent Supreme Court ruling on abortion rights.
• In June, the U.S. Supreme Court ruled 6-3 to overturn the landmark 1973 decision in Roe v. Wade, prompting several retailers to temporarily impose purchase limits on emergency contraceptive pills.

• After the ruling, Agile (AGRX) should benefit from tailwinds for its lead product Twirla — the only low dose transdermal hormonal contraceptive, the analyst Oren Livnat argued, reaffirming the Buy rating on the stock.

• The new price target $5.00, up from $2.50 per share previously, implies a premium of ~630% to the last close.
• Evofem Biosciences (EVFM), a company selling an FDA-approved birth control method, has outperformed Agile (AGRX) after the Roe v. Wade ruling, as shown in this graph.

Comments

[thehip]

I did not realize there was a garbage stock in existence that was not already in my portfolio.

[Bee202]

Massive POS … nothing will change until Leadership and/or BOD change!

[Dobbs99]

@Bee202 Unfortunately you are spot on. The CEO and senior management should have been canned a year ago.

[I_like_preferreds]

AGRX management disagree. They are dumping shares at 90 cents plus warrants.

[corvid]

Pump and dump on a $28 million market cap stock?
Lost 73.4% of stock price since June 22.

[dinoperson]

H.C. Wainwright has no credibility.

[thewalkar]

@dinoperson I ditto the opinion